Agios Pharmaceuticals (AGIO) and Its Competitors Head to Head Contrast

Agios Pharmaceuticals (NASDAQ: AGIO) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Agios Pharmaceuticals to related businesses based on the strength of its earnings, profitability, valuation, risk, analyst recommendations, institutional ownership and dividends.

Earnings & Valuation

This table compares Agios Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Agios Pharmaceuticals $69.89 million -$198.47 million -11.98
Agios Pharmaceuticals Competitors $290.27 million $35.99 million 58.74

Agios Pharmaceuticals’ rivals have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Agios Pharmaceuticals and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals 0 1 11 0 2.92
Agios Pharmaceuticals Competitors 1133 3423 11925 240 2.67

Agios Pharmaceuticals presently has a consensus target price of $75.70, suggesting a potential upside of 0.79%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.05%. Given Agios Pharmaceuticals’ rivals higher possible upside, analysts clearly believe Agios Pharmaceuticals has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

93.8% of Agios Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Agios Pharmaceuticals has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ rivals have a beta of 6.48, indicating that their average stock price is 548% more volatile than the S&P 500.

Profitability

This table compares Agios Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals -506.39% -69.64% -43.12%
Agios Pharmaceuticals Competitors -5,441.68% -162.70% -35.92%

Summary

Agios Pharmaceuticals rivals beat Agios Pharmaceuticals on 8 of the 13 factors compared.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply